Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -17.87% is 57% above its 5-year average of -41.88%, near the high end of its 5-year range (-92.33%–-16.49%).
50.53% above its 12-month average of -36.13%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.30%.
RETURN ON ASSETS (ROA)
-17.87%
RETURN ON ASSETS (ROA) AVG TTM
-36.13%
RETURN ON ASSETS (ROA) AVG 3Y
-48.35%
RETURN ON ASSETS (ROA) AVG 5Y
-41.88%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+50.53%
CURRENT VS 3Y AVG
+63.04%
CURRENT VS 5Y AVG
+57.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+44.61%
vs the sector median at left
Sagimet Biosciences Inc.
Market Cap
$285.42M
Return on Assets (ROA)
-17.87%
TTM Avg
-36.13%
3Y Avg
-48.35%
5Y Avg
-41.88%
Market Cap
$285.55M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$284.31M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
Market Cap
$282.64M
Return on Assets (ROA)
-13.93%
TTM Avg
-17.93%
3Y Avg
-26.92%
5Y Avg
-24.25%
Market Cap
$288.79M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$281.54M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$280.37M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
Market Cap
$292.59M
Return on Assets (ROA)
-96.57%
TTM Avg
-96.57%
3Y Avg
-96.57%
5Y Avg
-96.57%
Market Cap
$293.30M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sagimet Biosciences Inc. (SGMT) | $285.42M | -17.87% | -36.13% | -48.35% | -41.88% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | -35.03% | -13.04% | -43.14% | -55.84% |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | -18.18% | -10.00% | -29.10% | -54.94% |
| Standard BioTools Inc. (LAB)vs › | $282.64M | -13.93% | -17.93% | -26.92% | -24.25% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | -104.42% | -76.93% | -55.08% | -54.19% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | -26.24% | -12.09% | -27.60% | -33.24% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | -96.57% | -96.57% | -96.57% | -96.57% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | -128.66% | -214.31% | -145.75% | -133.94% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | -66.64% | -23.99% | -11.65% | -6.11% |
ROA
-17.9%
ROE
-18.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -43.82% |
| 2024-12-31 | -28.43% |
| 2023-12-31 | -28.82% |
| 2022-12-31 | -92.33% |
| 2021-12-31 | -41.40% |
| 2020-12-31 | -16.49% |
| 2019-12-31 | -127.79% |
